Alkylating agents, characterized by their ability to bind to and modify DNA, have shown promising impacts on breast cancer patients in clinical trials across various stages and phases. This review, utilizing data from the National Library of Medicine’s clinicaltrials.gov, investigates the efficacy of these drugs in breast cancer treatment. The report focuses on cyclophosphamide, an alkylating agent that prevents cancer cell DNA replication, and its synergistic effects when combined with other medications such as docetaxel, a taxane that suppresses cell division. Results indicate that these combination therapies may enhance treatment efficacy and improve outcomes. This survey highlights the widespread use of alkylating agents in clinical studies for breast cancer, a disease affecting over a million people annually in India alone. Commonly used alkylating drugs for breast cancer treatment include carmustine, chlorambucil, and cyclophosphamide. These agents have shown effectiveness in treating metastatic breast cancer and reducing the risk of recurrence, underscoring their significant role in breast cancer therapy.
World Health Organization. Global Breast Cancer Initiative Implementation Framework: Assessing, Strengthening and Scaling-up of Services for the Early Detection and Management of Breast Cancer. World Health Organization; 2023.
2.
XuH, XuB. Breast cancer: Epidemiology, risk factors and screening. Chin J Cancer Res, 2023; 35(6):565–583.
3.
FleegeNM, CobainEF. Breast cancer management in 2021: A primer for the obstetrics and gynecology. Best Practice Res Clin Obstetrics Gynaecol, 2022; 82:30–45.
4.
ColvinOM. An overview of cyclophosphamide development and clinical applications. Curr Pharm Des, 1999; 5(8):555–560.
5.
AhlmannM, HempelG. The effect of cyclophosphamide on the immune system: Implications for clinical cancer therapy. Cancer Chemother Pharmacol, 2016; 78(4):661–671.
6.
SørlieT, PerouCM, AasT, et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 2001; 98(19):10869–10874.
7.
EmamiF, JeongJH, YookS, et al.Bio-inspired and smart nanoparticles for triple negative breast cancer microenvironment. Pharmaceutics, 2021; 13(2):287.
8.
De LaurentiisM, CancelloG, D’AgostinoD, et al.Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol, 2008; 26(1):44–53.
9.
GreeneJ, HennessyB. The role of anthracyclines in the treatment of early breast cancer. J Oncol Pharm Pract, 2015; 21(3):201–212.
10.
FujiiT, Le DuF, XiaoL, et al.Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: A systematic review and network meta-analysis. JAMA Oncol, 2015; 1(9):1311–1318.
11.
HasnainMS, AhmadSA, HodaMN, et al.Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Application. In: Stimuli-Responsive carbon nanotubes for targeted drug delivery. Elsevier: Amsterdam, The Netherlands; 2019.
12.
EmadiA, JonesRJ, BrodskyRA. Cyclophosphamide and cancer: Golden anniversary. Nat Rev Clin Oncol, 2009; 6(11):638–647.
13.
DayD, FurlanA, IrvinE, et al.Simplified search strategies were effective in identifying clinical trials of pharmaceuticals and physical modalities. J Clin Epidemiol, 2005; 58(9):874.e1–874.e11.
14.
HaynesRB, McKibbonKA, WilczynskiNL, et al.; Hedges Team. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: Analytical survey. BMJ, 2005; 330(7501):1179.
15.
HunterKE, WebsterAC, PageMJ, et al.Searching clinical trials registers: Guide for systematic reviewers. BMJ, 2022 Apr 26;377:e068791.
16.
LefebvreC, GlanvilleJ, BriscoeS, et al.Searching for and selecting studies. Cochrane Handbook for Systematic Reviews of Interventions, 2019:67–107.
17.
ReinerB, ZamenhofS. Studies on the chemically reactive groups of deoxyribonucleic acids. J Biol Chem, 1957; 228(1):475–486.
18.
SharmaGN, DaveR, SharmaK, et al.Various types and management of breast cancer: An overview. J Adv Pharm Technol Res, 2010; 1(2):109–126.
19.
DawsonEK. Carcinoma in the mammary lobule and its origin. Edinb Med J, 1933; 40(2):57–82.
20.
SunY, NieG, WeiZ, et al.Luminal breast cancer classification according to proliferative indices: Clinicopathological characteristics and short-term survival analysis. Med Oncol, 2014; 31(7):55–59.
21.
CaldarellaA, CrocettiE, BianchiS, et al.Female breast cancer status according to ER, PR and HER2 expression: A population based analysis. Pathol Oncol Res, 2011; 17(3):753–758.
22.
Dean-ColombW, EstevaFJ. Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer, 2008; 44(18):2806–2812.
WieseDA, ThaiwongT, Yuzbasiyan-GurkanV, et al.Feline mammary basal-like adenocarcinomas: A potential model for human Triple-Negative Breast Cancer (TNBC) with basal-like subtype. BMC Cancer, 2013; 13:403–402.
25.
FinakG, SadekovaS, PepinF, et al.Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Research, 2006; 8(5):R58–R8.
26.
FrykbergER. Lobular carcinoma in situ of the breast. Breast J, 1999; 5(5):296–303.
27.
LiX, YinY, ShengX, et al.Distribution pattern of lymph node metastases and its implication in individualized radiotherapeutic clinical target volume delineation of regional lymph nodes in patients with stage IA to IIA cervical cancer. Radiat Oncol, 2015; 10:40–47.
28.
SakuragiN, SatohC, TakedaN, et al.Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer: Interdisciplinary Intr J American Cancer Society, 1999; 85(7):1547–1554.
29.
JabbourSK, LeeKH, FrostN, et al.Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage iii non–small cell lung cancer: The phase 2 keynote-799 nonrandomized trial. JAMA Oncol, 2021; 7(9):1–9.
30.
OllilaDW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol, 2006; 7(11):919–924.
31.
WarwickGP. The mechanism of action of alkylating agents. Cancer Res, 1963; 23(8_Part_1):1315–1333.
32.
DolanME, AnderssonBS, MurrayD, et al.Mechanisms of resistance to the toxicity of cyclophosphamide. CPD, 1999; 5(8):587–605.
33.
FuD, CalvoJA, SamsonLD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer, 2012; 12(2):104–120; doi: 10.1038/nrc3185
34.
MorettonA, LoizouJI. Interplay between cellular metabolism and the DNA damage response in cancer. Cancers (Basel), 2020; 12(8):2051.
35.
MolinaroC, MartoriatiA, CailliauK. Proteins from the DNA damage response: Regulation, dysfunction, and anticancer strategies. Cancers (Basel), 2021; 13(15):3819; doi: 10.3390/cancers13153819
36.
Bayat MokhtariR, HomayouniTS, BaluchN, et al.Combination therapy in combating cancer. Oncotarget, 2017; 8(23):38022–38043; doi: 10.18632/oncotarget.16723
37.
GateL, TewKD. Alkylating agents. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures, 2011:61–85.
38.
GoedeV, EichhorstB, FischerK, et al.Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma, 2015; 56(6):1585–1592.
39.
LuX, DingZC, CaoY, et al.Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J Immunol, 2015; 194(4):2011–2021.
40.
KalayciogluME, LichtinAE, AndresenSW, et al.High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer. Am J Clin Oncol, 1995; 18(6):491–494; doi: 10.1097/00000421-199512000-00007
41.
LalicH, AurerI, BatinicD, et al.Bendamustine: A review of pharmacology, clinical use and immunological effects (Review). Oncol Rep, 2022; 47(6):114; doi: 10.3892/or.2022.8325
42.
LoiblS, DoeringG, MüllerL, et al.Multicenter phase II study with weekly bendamustine and paclitaxel as first- or later-line therapy in patients with metastatic breast cancer: RiTa II Trial. Breast Care (Basel), 2011; 6(6):457–461; doi: 10.1159/000335199
43.
RinnerthalerG, GampenriederSP, PetzerA, et al.Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Results of a phase II trial (AGMT MBC-6). Ther Adv Med Oncol, 2021; 13:17588359211042301; doi: 10.1177/17588359211042301
44.
TelliML, JensenKC, VinayakS, et al.Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-Associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol, 2015; 33(17):1895–1901; doi: 10.1200/JCO.2014.57.0085
45.
SharmaP, SteckleinSR, YoderR, et al.Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT). Jco, 2022; 40(16_suppl):513; doi: 10.1200/JCO.2022.40.16_suppl.513
46.
DiérasV, HanHS, KaufmanB, et al.Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2020; 21(10):1269–1282.
47.
WeberGF. Molecular Therapies of Cancer. Springer; 2015.
48.
CH R, CH R. 2. Chemistry and Mechanism of Action. Cancer Therapeutics: Experimental and Clinical Agents; 1996.
49.
RalhanR, KaurJ. Alkylating agents and cancer therapy. Expert Opin Ther Pat, 2007; 17(9):1061–1075.
50.
EmensLA. Trastuzumab: Targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther, 2005; 12(3):243–253.
51.
MillerE, LeeHJ, LullaA, et al.Current treatment of early breast cancer: Adjuvant and neoadjuvant therapy. F1000Res, 2014; 3:198.
52.
MackeyJR, PieńkowskiT, CrownJ, et al.Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann Oncol, 2016; 27(6):1041–1047.
53.
WangY, CaoS, ChenY. Molecular treatment of different breast cancers. Anticancer Agents Med Chem, 2015; 15(6):701–720.
54.
MillardM, GallagherJD, OlenyukBZ, et al.A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. J Med Chem, 2013; 56(22):9170–9179.
55.
BonadonnaG, BrusamolinoE, ValagussaP, et al.Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med, 1976; 294(8):405–410.
56.
FeldbergD, PurandareN. Cancer therapy and reproductive impact. Intl J Gynecology & Obste, 2025; 169(3):891–894.
57.
PönischW, MitrouPS, MerkleKIII,et al.; East German Study Group of Hematology and Oncology (OSHO). Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase. Study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol, 2006; 132(4):205–212.
58.
PerezEA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist, 2004; 9(5):518–527; doi: 10.1634/theoncologist.9-5-518
59.
GursoyD, MalodiaS, DhirA. The metaverse in the hospitality and tourism industry: An overview of current trends and future research directions. J Hospitality Marketing Management, 2022; 31(5):527–534.
60.
MunozR, ManS, ShakedY, et al.Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res, 2006; 66(7):3386–3391.
61.
GouardS, PallardyA, GaschetJ, et al.Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy. Nucl Med Biol, 2014; 41:e30–e35.
62.
LiB, HeX, ZhuangM, et al.Melatonin ameliorates busulfan-induced spermatogonial stem cell oxidative apoptosis in mouse testes. Antioxid Redox Signal, 2018; 28(5):385–400.
63.
BegleiterA, MowatM, IsraelsLG, et al.Chlorambucil in chronic lymphocytic leukemia: Mechanism of action. Leuk Lymphoma, 1996; 23(3–4):187–201.
64.
SehnLH, ChuaN, MayerJ, et al.Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol, 2016; 17(8):1081–1093.
65.
HeymannD, OryB, BlanchardF, et al.Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone, 2005; 37(1):74–86.
66.
WangD, WangC, WangL, et al.A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment. Drug Deliv, 2019; 26(1):551–565.
67.
MoiranoSJ, DeweyCW, WrightKZ, et al.Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008–2017). Vet Comp Oncol, 2018; 16(4):459–466.
68.
HardyKM, StrizziL, MargaryanNV, et al.Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma. Mol Cancer Res, 2015; 13(4):670–680.
69.
YunB, GuZ, LiuZ, et al.Reducing chemo-/radioresistance to boost the therapeutic efficacy against temozolomide-resistant glioblastoma. ACS Appl Mater Interfaces, 2022; 14(34):38617–38630.
70.
StolinskyDC, SolomonJ, PughRP, et al.Clinical experience with procarbazine in Hodgkin’s disease, reticulum cell sarcoma, and lymphosarcoma. Cancer, 1970; 26(5):984–990.
71.
CapdevilaJ, DucreuxM, García CarboneroR, et al.Streptozotocin, 1982–2022: Forty years from the FDA’s approval to treat pancreatic neuroendocrine tumors. Neuroendocrinology, 2022; 112(12):1155–1167.
72.
WangCX, GuoSL, HanLN. Successful treatment of accessory breast cancer with endocrine therapy. J Zhejiang Univ Sci B, 2017; 18(1):70–75.
73.
RobertsNJ, ZhouS, Diaz JrLA, et al.Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget, 2011; 2(10):739–751.
74.
CranmerLD, TrevorKT, BandlamuriS, et al.Rodent models of brain metastasis in melanoma. Melanoma Res, 2005; 15(5):325–356.
75.
KhayatD, GirouxB, BerilleJ, et al.Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest, 1994; 12(4):414–420.
76.
MazurL, Opydo-ChanekM, StojakM, et al.Mafosfamide as a new anticancer agent: Preclinical investigations and clinical trials. Anticancer Res, 2012; 32(7):2783–2789.
77.
KlinkT, BelaC, StoeltingS, et al.Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. J Cancer Res Clin Oncol, 2006; 132(10):643–652.
78.
HiddemannW, Pott-HoeckC. Clinical trials with nucleoside analogs in lymphomas. In: Nucleoside Analogs in Cancer Therapy. CRC Press; 2021 (pp. 247–288).
79.
MazurL, Opydo-ChanekM, StojakM. Glufosfamide as a new oxazaphosphorine anticancer agent. Anticancer Drugs, 2011; 22(6):488–493.
80.
BorgesAF, LaurindoFJ, SpínolaMM, et al.The strategic use of artificial intelligence in the digital era: Systematic literature review and future research directions. Int J Inf Manage, 2021; 57:102225.
81.
BhatiaK, DasA, Bhumika. Combinatorial drug therapy in cancer-New insights. Life Sci, 2020; 258:118134.
82.
AyoubNM. Novel combination therapies for the treatment of solid cancers. Front Oncol, 2021; 11:708943.
83.
WataseC, ShiinoS, ShimoiT, et al.Breast cancer brain metastasis—overview of disease state, treatment options and future perspectives. Cancers (Basel), 2021; 13(5):1078.
84.
PenelN, AdenisA, BocciG. Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol, 2012; 82(1):40–50.
85.
ZhuY, HuY, TangC, et al.Platinum-based systematic therapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer, 2022; 1877(1):188678.
86.
SalviVR, PawarP. Nanostructured Lipid Carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol, 2019; 51:255–267.
87.
FarooqMA, AquibM, FarooqA, et al.Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: An overview. Artif Cells Nanomed Biotechnol, 2019; 47(1):1674–1692.
88.
LaffleurF, KeckeisV. Advances in drug delivery systems: Work in progress still needed? Int J Pharm, 2020; 590:119912.
89.
ChaurasiyaP, GanjuE, UpmanyuN, et al.Transfersomes: A novel technique for transdermal drug delivery. J Drug Delivery Ther, 2019; 9(1):279–285.
90.
DongJ, WuZ, XuH, et al.FormulationAI: A novel web-based platform for drug formulation design driven by artificial intelligence. Brief Bioinform, 2023; 25(1):bbad419.
91.
FaresJ, KanojiaD, RashidiA, et al.Landscape of combination therapy trials in breast cancer brain metastasis. Int J Cancer, 2020; 147(7):1939–1952.
92.
ZanardiE, BregniG, de BraudF, et al.Better together: Targeted combination therapies in breast cancer. Semin Oncol, 2015; 42(6):887–895. WB Saunders.
93.
WangY, MindenA. Current molecular combination therapies used for the treatment of breast cancer. Int J Mol Sci, 2022; 23(19):11046; doi: 10.3390/ijms231911046
94.
KaurR, BhardwajA, GuptaS. Cancer treatment therapies: Traditional to modern approaches to combat cancers. Mol Biol Rep, 2023; 50(11):9663–9676.
95.
LinkW. Principles of Cancer Treatment and Anticancer Drug Development. Springer International Publishing: Cham; 2019.
96.
JonesS, HolmesFA, O’ShaughnessyJ, et al.Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol, 2009; 27(8):1177–1183.
97.
MoscaL, IlariA, FaziF, et al.Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resist Updat, 2021; 54:100742; doi: 10.1016/j.drup.2020.100742
98.
ZhangC, XuC, GaoX, et al.Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics, 2022; 12(5):2115–2132; doi: 10.7150/thno.69424
99.
YinL, DuanJ-J, BianX-W, et al.Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res, 2020; 22(1):61.
100.
GronwaldJ, ByrskiT, LubinskiJ, et al.Cisplatin in breast cancer treatment in BRCA1 carriers. Hered Cancer Clin Pract, 2012; 10(Suppl 4):A17; doi: 10.1186/1897-4287-10-S4-A17
101.
SledgeGW, LoehrerPJ, RothBJ, et al.Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol, 1988; 6(12):1811–1814; doi: 10.1200/JCO.1988.6.12.1811
102.
LauKH, TanAM, ShiY. New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci, 2022; 23(4):2288.
103.
LambrechtsY, WildiersH, FlorisG, et al.Dissection of molecular determinants of metastasis and detailed characterization of the age-related immunological profile in (older) patients with hormone-sensitive breast cancer. 2025.
104.
PernasS, TolaneySM. HER2-positive breast cancer: New therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol, 2019; 11:1758835919833519.
105.
AndreopoulouE, SchweberSJ, SparanoJA, et al.Therapies for triple negative breast cancer. Expert Opin Pharmacother, 2015; 16(7):983–998.
106.
LangstonAA, MaloneKE, ThompsonJD, et al.BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med, 1996; 334(3):137–142.
LiuJ, CabralH, MiP. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release. Adv Drug Deliv Rev, 2024; 207:115239.
109.
DuanC, YuM, XuJ, et al.Overcoming cancer Multi-Drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed Pharmacother, 2023; 162:114643.
110.
ManzariMT, ShamayY, KiguchiH, et al.Targeted drug delivery strategies for precision medicines. Nat Rev Mater, 2021; 6(4):351–370.
111.
SahaM, SarkarA. Review on multiple facets of drug resistance: A rising challenge in the 21st century. J Xenobiot, 2021; 11(4):197–214.
112.
GargP, MalhotraJ, KulkarniP, et al.Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancers (Basel), 2024; 16(13):2478.
113.
GavandeNS, VanderVere-CarozzaPS, HinshawHD, et al.DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther, 2016; 160:65–83; doi: 10.1016/j.pharmthera.2016.02.003
114.
MalikJA, AhmedS, JanB, et al.Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges. Biomed Pharmacother, 2022; 145:112375.
115.
LiuR, ChenY, LiuG, et al.PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis, 2020; 11(9):797.
116.
SaxenaR, DwivediA. ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Med Res Rev, 2012; 32(1):166–215.
117.
ShanaahHH, AllangawiA, ALZaimoorEF, et al.Recent advancements in the chemical sensing of anticancer alkylating agents. Chem Pap, 2024; 78(17):8941–8964.
118.
DamiaG and D‘IncalciM. Mechanisms of resistance to alkylating agents. Cytotechnology, 1998; 27(1–3):165–173.
119.
WilliamsSA, SchreierAM. The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum, 2004; 31(1):E16–E23.
120.
KwokC. Management of side effects from chemotherapy. The Hongkong anti Cancer Society, 2010:12–16.
121.
Lotfi-JamK, CareyM, JeffordM, et al.Nonpharmacologic strategies for managing common chemotherapy adverse effects: A systematic review. J Clin Oncol, 2008; 26(34):5618–5629.
122.
Brianna, LeeSH. Chemotherapy: How to reduce its adverse effects while maintaining the potency? Med Oncol, 2023; 40(3):88.
123.
HaH, LimJH. Managing side effects of cytotoxic chemotherapy in patients with high grade gliomas. Brain Tumor Res Treat, 2022; 10(3):158–163.
124.
AppelE. Side effects of chemotherapy and their management. Microreviews in Cell and Molecular Biology, 2023.
125.
HanHK, AmidonGL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci, 2000; 2(1):E6–E58.
126.
BibaultJE, FumagalliI, FertéC, et al.Personalized radiation therapy and biomarker-driven treatment strategies: A systematic review. Cancer Metastasis Rev, 2013; 32(3–4):479–492.
127.
Krishna VadlapatlaR, Dutt VadlapudiA, PalD, et al.Mechanisms of drug resistance in cancer chemotherapy: Coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des, 2013; 19(40):7126–7140.
128.
LuB, NatarajanE. Combination therapy strategies and advanced biomarkers can potentially enhance the precision-medicine treatment of metastatic breast cancer. J Natural Sci, Biolo Med, 2024; 15(2):266.
129.
JoergerM, KosterKL, JanikT, et al.Combination therapy with immune checkpoint inhibitors and histone deacetylase inhibitors or alkylating agents. Cancer Manag Res, 2024; 16Dec 31:855–869.
130.
HoueisL, van der PlanckeG, WenJY, et al.Chemotherapy-induced diminished murine ovarian reserve model and impact of low-dose chemotherapy on fertility. F S Sci, 2025; 6(2):177–185.
131.
OrdituraM, De VitaF, RoscignoA, et al.Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review). Oncol Rep, 1999; 6(6):1357–1362; doi: 10.3892/or.6.6.1357
132.
O’ShaughnessyJA. Oral alkylating agents for breast cancer therapy. Drugs, 1999; 58(Suppl 3):1–9.
133.
PuyoS, MontaudonD, PourquierP. From old alkylating agents to new minor groove binders. Crit Rev Oncol Hematol, 2014; 89(1):43–61.
134.
ColeyHM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev, 2008; 34(4):378–390.
